Chinese Real-world Study of Treatment of Vestibular Migraine

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

2000 participants

Study Classification

OBSERVATIONAL

Study Start Date

2025-12-31

Study Completion Date

2028-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Vestibular migraine is a phenotype of migraine, characterized by more prominent vertigo symptoms compared to headache. Treatments for VM are mainly divided into two categories: acute treatment and preventive treatment. Acute treatment aims to reduce the severity and duration of a single episode, while preventive treatment aims to decrease the frequency, severity, and duration of attacks. Current acute treatments are primarily divided into pain relief and anti-dizziness, with specific drugs such as triptans and ergots being applicable for pain relief, but only betahistine has weak evidence for anti-dizziness, and relevant clinical evidence is very scarce. Preventive treatment mainly refers to migraine preventive treatments, with recommended medications including traditional drugs like topiramate, flunarizine, propranolol, etc., but the efficacy and safety of these drugs are limited. CGRP-targeted drugs are believed to play a role in the preventive treatment of VM, and there are related literature reports, but most are small-sample studies or retrospective studies. This study aims to explore the real-world efficacy of CGRP-targeted drugs in the acute and preventive treatment of VM through a prospective real-world study.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

China Headache and Vertigo Registry Study

NCT04939922

Headache Disorders, Primary Headache Disorders, Secondary Migraine +5 more

RECRUITING

International Headache Registry Study

NCT05418218

Headache Disorders, Primary Headache Disorders, Secondary Migraine +4 more

RECRUITING

A Clinical Trial of Rimegepant for Vestibular Migraine Evaluation: Pre-experiment

NCT06748664

Vestibular Migraine Adults 18 Years and Older (no Other Exclusion Criteria)

NOT_YET_RECRUITING PHASE2

Does a Migraine Medication Decrease Rotational Motion Sickness in People Suffering From Migraines?

NCT00360282

Migraine

COMPLETED NA

4-Aminopyridine, Atenolol, or Placebo in Patients With Vestibular Migraine

NCT03578354

Vestibular Migraine Migraine Disorders Vestibular Diseases

WITHDRAWN PHASE2

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Vestibular Migraine Dizziness Vertigo

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A1

Group A is the acute treatment group, which will observe the effectiveness of medication used for acute treatment after a VM (Vestibular Migraine) attack in the participants. Subgroup A1 will include participants who undergo acute treatment with CGRP-targeted drugs.

CGRP R Inhibitor; CGRP Inhibitor

Intervention Type DRUG

Participants who are prescribed CGRP class drugs for the acute treatment of VM will be considered for inclusion in Group A1.Participants who are prescribed CGRP class drugs for the preventive treatment of VM will be considered for inclusion in Group B1.

A2

Group A is the acute treatment group, which will observe the effectiveness of medication used for acute treatment after a VM (Vestibular Migraine) attack in the participants. Subgroup A2 will include participants who undergo acute treatment with medications other than CGRP drugs (such as NSAIDs, triptans, etc.).

none-CGRP

Intervention Type DRUG

Participants who are prescribed none-CGRP class drugs for the acute treatment of VM will be considered for inclusion in Group A2.Participants who are prescribed none-CGRP class drugs for the preventive treatment of VM will be considered for inclusion in Group B2.

B1

Group B is the preventive treatment group, which will observe the efficacy of 12-week prophylactic medication in participants. Subgroup B1: Patients receiving CGRP-targeted drugs (e.g., CGRP monoclonal antibodies or gepants) for preventive treatment.

CGRP R Inhibitor; CGRP Inhibitor

Intervention Type DRUG

Participants who are prescribed CGRP class drugs for the acute treatment of VM will be considered for inclusion in Group A1.Participants who are prescribed CGRP class drugs for the preventive treatment of VM will be considered for inclusion in Group B1.

B2

Group B is the preventive treatment group, which will observe the efficacy of 12-week prophylactic medication in participants. Subgroup B2: Patients receiving non-CGRP preventive medications (e.g., flunarizine, topiramate, propranolol, etc.).

none-CGRP

Intervention Type DRUG

Participants who are prescribed none-CGRP class drugs for the acute treatment of VM will be considered for inclusion in Group A2.Participants who are prescribed none-CGRP class drugs for the preventive treatment of VM will be considered for inclusion in Group B2.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

CGRP R Inhibitor; CGRP Inhibitor

Participants who are prescribed CGRP class drugs for the acute treatment of VM will be considered for inclusion in Group A1.Participants who are prescribed CGRP class drugs for the preventive treatment of VM will be considered for inclusion in Group B1.

Intervention Type DRUG

none-CGRP

Participants who are prescribed none-CGRP class drugs for the acute treatment of VM will be considered for inclusion in Group A2.Participants who are prescribed none-CGRP class drugs for the preventive treatment of VM will be considered for inclusion in Group B2.

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. Male or female, aged between 18 and 75 years.
2. Meet the following criteria established by the Barany Society for the diagnosis of vestibular migraine or probable vestibular migraine:

Vestibular Migraine A: At least five episodes with moderate or severe vestibular symptoms lasting from 5 minutes to 72 hours.

B: Current or past history of migraine, with or without aura, according to the International Classification of Headache Disorders (ICHD-3).

C: One or more migraine features during at least 50% of vestibular episodes:

Headache with at least two of the following characteristics: unilateral, pulsating, moderate or severe pain, worsening with routine physical activity.

Photophobia and phonophobia. Visual aura. D: Not better accounted for by another vestibular or ICHD diagnosis. Probable Vestibular Migraine A. At least five episodes with moderate or severe vestibular symptoms lasting from 5 minutes to 72 hours.

B. Meets only one of the criteria B or C for vestibular migraine (history of migraine or migraine features during episodes).

C. Not better accounted for by another vestibular or ICHD diagnosis.
3. More than or equal to 4 days per month with confirmed vestibular symptom in the three months prior to enrollment (only required for group B).
4. Able to complete at least 80% of the electronic diary during the treatment period.
5. The investigator believes that the participant is able to read, understand, and complete the study questionnaires and headache diary.

Understanding and compliance with the study procedures and methods, voluntary participation in this trial, and written informed consent.

Exclusion Criteria

1. Pregnant women, breastfeeding women, or those unwilling to use approved contraceptive methods during study participation.
2. Presence of a condition or abnormality that the investigator believes would affect the safety of the patient or the quality of the data.
3. History of ear surgery (excluding ear tube surgery).
4. Other vestibular diagnoses (excluding treated benign paroxysmal positional vertigo, BPPV). This includes Ménière's disease, superior semicircular canal dehiscence syndrome, vestibular neuritis, persistent postural-perceptual dizziness, unilateral or bilateral vestibular hypofunction, cerebellar or brainstem disorders, multiple sclerosis, or seasickness.
5. More than two preventive migraine medications have failed.
6. Previous or current treatment with CGRP class drugs.
7. History of serious medical or psychiatric conditions, as judged by the treating physician (including significant coronary artery disease, peripheral vascular disease, cerebrovascular disease, renal disease, liver disease, Raynaud's disease, uncontrolled psychiatric illness, or past psychiatric hospitalization).
8. History of mania, psychosis, or suicidal ideation.
9. Acceptable if using no more than two migraine preventive medications (prescribed specifically for this purpose), with stable dosing for at least 2 months prior to study start.
10. History of drug or alcohol abuse within the 12 months prior to screening, based on the participant's medical records or self-report.
11. Those who have received or plan to receive botulinum toxin (e.g., Dysport®, Botox®, Xeomin®, Myobloc®, Jeuveau™) for therapeutic or cosmetic purposes in the head, face, or neck within 4 months prior to screening or during the study period.

Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No